# Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Study · id `cardio:ct-nct02864953` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02864953](<https://clinicaltrials.gov/study/NCT02864953>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02864953

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 535 participants.

## Technical summary

Registry record NCT02864953. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-29 (actual); primary completion 2023-08-18 (actual). Results posted on 2024-01-09.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 535 participants (enrolled count; ClinicalTrials.gov record NCT02864953, source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)
- Started: 2018-08-29 (actual) (ClinicalTrials.gov record NCT02864953, source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)
- Primary completion: 2023-08-18 (actual) (ClinicalTrials.gov record NCT02864953, source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)
- Completion: 2023-08-18 (actual) (ClinicalTrials.gov record NCT02864953, source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)
- Results first posted: 2024-01-09 (ClinicalTrials.gov record NCT02864953, source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Brazil; Canada; China; Croatia; Czechia; Denmark; Finland; France; Germany; Hungary; Israel; Italy; Japan; Lithuania; Portugal; Russia; South Korea; Spain; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT02864953, source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02864953-2024-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
- Acronym: CHARM
- Condition: Brain Edema
- Condition: Stroke, Acute
- Intervention (Drug): BIIB093
- Intervention (Drug): Placebo
- Lead sponsor: Remedy Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial (`cardio:pubmed-39577921`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e73c9c1d28c5da525be8f14cabf56ab43fa5a51e6cc60866ce8caaf312716db5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
